Contents of this tag:

1. 1 2019-12-27T04:00:19-08:00 Ken Londoner 67400b6d41c00fbf11f194dad77d72364b87b2e2 BioSig Technologies Presentation at Venice Arrhythmias 2019 1 plain 2019-12-27T04:00:24-08:00 Ken Londoner 67400b6d41c00fbf11f194dad77d72364b87b2e2

This page is referenced by:

• 1 2019-12-27T04:00:19-08:00 BioSig Technologies Presentation at Venice Arrhythmias 2019 1 plain 2019-12-27T04:00:24-08:00 Westport-based medical technology company BioSig Technologies, has been developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace. Recently, introduced its PURE EP System in a poster presentation at the Venice Arrhythmias conference being held on October 3-5, 2019 in Venice, Italy.
  The Venice Arrhythmias biennial event focuses on the most important topics for research, therapies and clinical practice for the treatment of cardiac arrhythmias. Over the years it has become a place of reference, where many personalities have shared their great progress, where many young doctors, confirmed and sustained in their ideas, have found the opportunity to grow professionally and become in turn the greatest experts.
  
  The clinical data poster presented by BioSig Technologies titled, "Use of a Novel Intracardiac Signal Processing System during Mapping of Complex Cardiac Arrhythmias" was prepared by an entire team of outstanding physicians and EP lab staff members at Texas Cardiac Arrhythmia Institute. The data was collected during two atrial fibrillation cases conducted with PURE EP System in February 2019.
  After conducting first clinical cases at Texas Cardiac Arrhythmia Institute in February 2019 BioSig successfully carried out further patient cases using its PURE EP System at Greenville Memorial Hospital in Greenville, SC and Indiana University School of Medicine. The company also signed three new licensing agreements with Mayo Clinic.
  The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms.
  Company's CEO, Kenneth Londoner said BioSig's goal is to deliver a technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP System in August 2018.
  As the firm continues to expand, Londoner said he is looking forward to contributing and raising awareness of BioSig within fundamentals-driven institutional community.